4.4 Review

Discontinuation of bisphosphonates in seniors: a systematic review on health outcomes

期刊

ARCHIVES OF OSTEOPOROSIS
卷 16, 期 1, 页码 -

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s11657-021-01000-w

关键词

Deprescribing; Bisphosphonates; Osteoporosis; Older adults; Systematic review

资金

  1. Canadian Institutes of Health Research [2016-18]
  2. Reseau Quebecois de recherche sur le vieillissement-FRQS
  3. Centre d'excellence sur le vieillissement de Quebec/CIUSSS de la Capitale Nationale

向作者/读者索取更多资源

Bisphosphonates can be successfully discontinued after at least 3 years of use, with low overall fracture risk. However, there is a risk for decreased BMD and increased vertebral fractures upon discontinuation according to some studies.
Purpose Bisphosphonates are used to treat osteoporosis. Despite their benefits on bone mineral density (BMD) and fractures, they have shown adverse effects, sometimes severe, during chronic use. Taken for several years, they achieve long-term bone retention, making deprescribing feasible. This review aimed to synthesize evidence on the success and health outcomes of deprescribing of bisphosphonates in seniors, aged over 60 years. Methods The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including articles in English, French, or German published before July 2020. Eligible studies included seniors having discontinued bisphosphonates and reported on health outcomes; some allowed meta-analyses on fracture risk. Results The review included 9 RCTs and 9 cohort studies of moderate quality. Bisphosphonates were discontinued after 2 to 7 years of use, and BMD or fractures were assessed during follow-up of 0.5 to 5 years. A significant reduction in BMD after discontinuation was observed in 9 of 10 studies. Results on fracture risk after discontinuation are mitigated: 6 RCT extensions showed no increase in the risk of any osteoporotic fractures after discontinuation. Meta-analyses including 4 RCTs showed an increased odds ratio of vertebral fractures of 2.04 (95% CI, 1.39-2.99) among discontinuers. Results from 2 large cohort studies showed no increased risks of any osteoporotic or vertebral fractures, while 2 studies found increased fracture risks. Conclusion Bisphosphonates have successfully been discontinued low overall fracture risk after at least 3 years of use, but a risk for decreased BMD and increased vertebral fractures remained.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据